290371-79-8

Basic information

• Product Name: (5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5-carbonitrile
• Synonyms: (5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5-carbonitrile
• CAS NO: 290371-79-8
• Molecular Weight: 409.395
• Mol File: 290371-79-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5-carbonitrile(290371-79-8)
• EPA Substance Registry System: (5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5-carbonitrile(290371-79-8)

Safety Data

• Hazardous Substances Data: 290371-79-8(Hazardous Substances Data)

Upstream product

• 6559-91-7 4'-demethylepipodophyllotoxin 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 327082-16-6 C₃₀H₂₉NO₈ 
• 1252007-82-1 C₃₄H₃₅NO₈ 
• 1252007-81-0 C₂₆H₃₀N₂O₈ 
• 1252007-80-9 C₃₀H₃₀N₂O₈ 
• 1252007-79-6 C₃₄H₃₆N₂O₈ 
• 1252007-76-3 C₂₉H₃₄N₂O₈ 
• 1252007-73-0 C₂₈H₃₂N₂O₉ 
• 1252007-63-8 C₃₂H₃₂N₂O₉ 
• 278618-79-4 (5S,5aS,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5-carboxylic acid 

Relevant articles and documents

Isolation, Semisynthesis, and Molecular Modeling of Deoxypodophyllotoxin Analogs for an Anti-oral Cancer Agent

-

Antitumor agents. Part 227: Studies on novel 4′-O-demethyl- epipodophyllotoxins as antitumor agents targeting topoisomerase II

Eight novel epipodophyllotoxin derivatives (6-13), which were designed to overcome drug resistance and enhance topoisomerase II inhibition, were synthesized and evaluated. Two of these compounds (7 and 8) showed better preclinical activity profiles, inclu